Silence Therapeutics said this week that it has identified the maximum tolerated dose for its siRNA-based cancer treatment Atu027 and that the drug has proven safe and well-tolerated in a nearly complete phase I trial.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.
Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.
Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.
Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.